Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol

Tarig Mohammed Abkur; Mamoun Saeed; Saad Zeinalabdin Ahmed; Ryan McArthur; Maeve Leahy; Hilary O'Leary; Denis O'Keeffe

doi:10.1002/ccr3.195

Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol

Clin Case Rep. 2015 Apr;3(4):255-9. doi: 10.1002/ccr3.195. Epub 2015 Feb 9.

Authors

Tarig Mohammed Abkur¹, Mamoun Saeed¹, Saad Zeinalabdin Ahmed¹, Ryan McArthur², Maeve Leahy³, Hilary O'Leary³, Denis O'Keeffe³

Affiliations

¹ Department of Haematology, University Hospital Limerick Limerick, Ireland.
² Graduate Entry Medical School, University of Limerick Limerick, Ireland.
³ Department of Haematology, University Hospital Limerick Limerick, Ireland ; Graduate Entry Medical School, University of Limerick Limerick, Ireland.

Abstract

The decision for PJP prophylaxis depends on a physician's evaluation of multiple variables. The high rate of PJP infection described in this article combined with the known impaired T-cell function post Bendamustine treatment justifies considering all patients for PJP prophylaxis when they receive Bendamustine treatment.

Keywords: Bendamustine; Pneumocystis; Trimethoprim/Sulfamethoxazole.

Publication types

Case Reports